Frequently Asked Questions about Definium Therapeutics, Inc. (DFTX)

Name: Definium Therapeutics, Inc. (DFTX) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Definium Therapeutics, Inc. (DFTX) do?

Accepted Answer

Definium Therapeutics, Inc. is a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder;...

Question 2

Is Definium Therapeutics, Inc. (DFTX) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of DFTX reveals an Altman Z-Score of 9.76 and a Piotroski F-Score of 2/9. These metrics, combined with its 5-year revenue trend ($0.00B most recent), help investors decide if DFTX fits their risk profile.

Question 3

What is the current P/E ratio for DFTX?

Accepted Answer

As of the latest trading session, Definium Therapeutics, Inc. (DFTX) has a trailing P/E ratio of -10.50.

Question 4

Who is the CEO of Definium Therapeutics, Inc.?

Accepted Answer

The current Chief Executive Officer of Definium Therapeutics, Inc. is Robert Barrow.

Question 5

What was DFTX's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Definium Therapeutics, Inc. reported annual revenues of $0.00B (2025), $0.00B (2024), $0.00B (2023), $0.00B (2022), $0.00B (2021) respectively.

Question 6

Does DFTX pay a dividend?

Accepted Answer

Definium Therapeutics, Inc. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does DFTX have?

Accepted Answer

In its latest reporting period, Definium Therapeutics, Inc. generated $-0.13B in Free Cash Flow against a total debt load of $N/A.

Question 8

What is the Price-to-Book (P/B) ratio of Definium Therapeutics, Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for Definium Therapeutics, Inc. (DFTX) is currently 5.81.

Question 9

What is the Price-to-Sales (P/S) ratio of DFTX?

Accepted Answer

Based on trailing twelve-month data, Definium Therapeutics, Inc. (DFTX) trades at a Price-to-Sales (P/S) ratio of 0.00.

Question 10

What is Definium Therapeutics, Inc.'s Return on Equity (ROE)?

Accepted Answer

Definium Therapeutics, Inc. (DFTX) has a Return on Equity (ROE) of -84.39%, representing its profitability relative to shareholder equity.

DFTX

Definium Therapeutics to Participate at Upcoming Investor Conferences and Events

Definium Therapeutics to Participate at Upcoming Investor Conferences and Events

Definium Therapeutics, Inc. (NASDAQ:DFTX) Given Average Rating of “Buy” by Analysts

New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States

Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics, Inc. (NASDAQ:DFTX) Short Interest Update

Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026